BioNTech (NASDAQ:BNTX) Earns “Buy” Rating from HC Wainwright

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $150.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 40.98% from the company’s current price.

Several other analysts have also weighed in on BNTX. TD Cowen lowered their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Bank of America boosted their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and boosted their target price for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, UBS Group raised their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $138.79.

BioNTech Trading Up 4.4 %

Shares of BNTX opened at $106.40 on Monday. BioNTech has a one year low of $76.53 and a one year high of $131.49. The stock has a 50-day moving average price of $113.68 and a 200 day moving average price of $97.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $25.51 billion, a P/E ratio of -50.67 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.73 EPS. Sell-side analysts forecast that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC lifted its stake in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares during the period. Covestor Ltd increased its stake in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Capital International Sarl lifted its stake in BioNTech by 1.3% during the first quarter. Capital International Sarl now owns 24,058 shares of the company’s stock valued at $2,219,000 after buying an additional 310 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.